Maria Terrones-Peinador

Maria Terrones-Peinador

Auto-generated profile, based on publicly available information

Maria Terrones-Peinador

Internal Medicine Department, Vall d'Hebron University Hospital, Barcelona, Catalunya, Spain

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2022 in BMJ Case Reports
Verified
Journal Article
Closed access
PDF file
MTMaría Terrones-Peinador
María Terrones-Peinador
SESimeón Eremiev-Eremiev
Simeón Eremiev-Eremiev
CPCarlos Pigrau-Serrallach
Carlos Pigrau-Serrallach
RSRoser Solans-Laque
Roser Solans-Laque
Whipple’s disease (WD) is a rare infectious disease with a wide clinical spectrum. Associated thrombotic manifestations are not well described in WD, only related to ‘stroke-like syndrome’. We present a case of a 39-year-old man with a 1-year history of self-limited episodes of fever, associated with generalised adenopathies and recurrent superficial and deep venous thrombosis events, which have resorted four times despite the anticoagulant treatment. Finally, the patient is diagnosed with WD. Following treatment the patient improved in his general condition, and no more episodes of fever neither thrombosis appeared during a follow-up of more than 3 years.

1 September 2020 in Indian Journal of Rheumatology
Verified
Journal Article
Open access
ASAlbert Selva-O'Callaghan
Albert Selva-O'Callaghan
MTMaria Terrones-Peinador
Maria Terrones-Peinador
JMJoana Rita Marques-Soares
Joana Rita Marques-Soares
AGAlbert Gil-Vila
Albert Gil-Vila
There is an intriguing relationship between cancer and myositis. The immunosuppressive agents commonly used to treat myositis patients are known to favor the development of cancer, but this factor does not seem to be the main cause of the association. Most myositis patients who develop cancer are considered to have cancer-associated myositis, which suggests that there are some types of etiopathogenic relationship between these two conditions. The malignancy usually appears within 3 years of the myositis diagnosis, and the risk of cancer depends on the myositis phenotype, with classic or amyopathic dermatomyositis (DM) and immune-mediated necrotizing myopathy being the main associated phenotypes. Several considerations regarding the pathogenesis of this association and strategies to detect occult malignancy in these patients are discussed here, with special emphasis on the role of autoantibodies as markers of this condition. Anti- TIF1g (Transcription Intermediary Factor 1 gamma) antibodies have been extensively studied in patients with cancer-associated DM. In addition, we discuss the peculiarities of treating patients with cancer-associated myositis and suggest some good treatment options, and finally, we examine the cancer–myositis relationship with regard to the recently described concept of myositis as an immune-related adverse event derived from the use of checkpoint immune inhibitors to treat cancer.